CathVision Appoints Eric Thepaut as Independent Chairman and Releases ECGenius Version 3.5
Written by Emily J. Thompson, Senior Investment Analyst
Source: Newsfilter
Updated: 56 minutes ago0mins
- Leadership Change: CathVision appoints Eric Thepaut as Independent Chairman, who previously served as President, EMEA at Boston Scientific, bringing extensive experience in global commercial operations that will strategically guide the company’s growth in cardiac electrophysiology.
- Product Release: The launch of Version 3.5 of the ECGenius® System introduces multiple hardware and software enhancements aimed at improving workflow efficiency and system performance, thereby increasing operational efficiency for clinicians treating cardiac arrhythmias.
- Market Expansion Preparation: With ECGenius and Cardialytics receiving FDA clearance in 2023 and CE marking in 2025, CathVision is preparing for commercial growth in the U.S. and Europe, indicating strong potential for expansion in the cardiac electrophysiology market.
- Technological Innovation: Updates in Version 3.5 include user interface flexibility and IT integration features, reflecting physician feedback and aimed at enhancing overall performance of the ECGenius system by improving documentation efficiency and reducing post-pacing artifacts.
BSX.N
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BSX is 126.76 USD with a low forecast of 113.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
24 Analyst Rating
23 Buy
1 Hold
0 Sell
Strong Buy
Current: 93.840
Low
113.00
Averages
126.76
High
140.00
Current: 93.840
Low
113.00
Averages
126.76
High
140.00
Morgan Stanley
Patrick Wood
Overweight
maintain
$125 -> $130
2025-10-23
Reason
Morgan Stanley
Patrick Wood
Price Target
$125 -> $130
2025-10-23
maintain
Overweight
Reason
Morgan Stanley analyst Patrick Wood raised the firm's price target on Boston Scientific to $130 from $125 and keeps an Overweight rating on the shares. The firm, which updated its model following Q3 results, notes it is making "modest changes" in light of the company's most recent guidance and long-range targets.
Truist
Buy
maintain
$129 -> $130
2025-10-23
Reason
Truist
Price Target
$129 -> $130
2025-10-23
maintain
Buy
Reason
Truist raised the firm's price target on Boston Scientific to $130 from $129 and keeps a Buy rating on the shares. The company reported a solid Q3 earnings beat, with accelerating Watchman growth seen as the standout, the analyst tells investors in a research note. Truist adds it is confident that Boston Scientific can still deliver upside to a now higher guidance, the firm added.
Wells Fargo
Overweight
maintain
$124 -> $125
2025-10-23
Reason
Wells Fargo
Price Target
$124 -> $125
2025-10-23
maintain
Overweight
Reason
Wells Fargo raised the firm's price target on Boston Scientific to $125 from $124 and keeps an Overweight rating on the shares. The firm reported Q3 revenue/EPS ahead of Street on strong PFA and Watchman strength. Q4 organic revenue and EPS guidance were ahead of Wells' estimates. The firm believes that 10% organic growth in 2026 is a reasonable starting point. CHAMPION-AF data in early 2026 is next catalyst, Wells adds.
UBS
Buy
maintain
$135 -> $140
2025-10-23
Reason
UBS
Price Target
$135 -> $140
2025-10-23
maintain
Buy
Reason
UBS raised the firm's price target on Boston Scientific to $140 from $135 and keeps a Buy rating on the shares following the Q3 report. The company's momentum is not slowing down following another quarter of organic sales and earnings growth above consensus, the analyst tells investors in a research note. UBS believes Boston Scientific continues to benefit from the "most positive product cycle in all of large-cap MedTech."
See All Ratings
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What does the 69% rating for BSX indicate about its fundamentals?
How does Peter Lynch's investment philosophy apply to Boston Scientific Corp?
Will Boston Scientific's advancements in cardiology sustain its 8-10% annual growth?
How might ETF outflows impact Boston Scientific's stock performance in the future?